The latest Investing Matters Podcast episode featuring Jeremy Skillington, CEO of Poolbeg Pharma has just been released. Listen here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksElementis Regulatory News (ELM)

Share Price Information for Elementis (ELM)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 138.00
Bid: 138.80
Ask: 139.00
Change: -4.60 (-3.23%)
Spread: 0.20 (0.144%)
Open: 142.20
High: 142.20
Low: 137.20
Prev. Close: 142.60
ELM Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

2019 Capital Markets Day

19 Nov 2019 07:00

RNS Number : 8139T
Elementis PLC
19 November 2019
 

Elementis Plc 

2019 Capital Markets Day

Innovation. Growth. Efficiency.

Clear medium term financial and performance objectives

 

Elementis will hold a Capital Markets Day for analysts and investors today to provide an update on its strategy. With strong positions in attractive markets we see clear growth and margin improvement opportunities and expect to deliver strong, sustainable returns over the medium term.

Clear medium term Group performance objectives

- Adjusted operating profit margin of 17%

- Operating cash conversion of at least 90% per annum

- Financial leverage of under 1.5x net debt/EBITDA

Paul Waterman, CEO of Elementis Plc commented

"Elementis has made significant progress over the last three years to transform its portfolio and to re-position itself as a premium performance additives company with advantaged positions in growing markets. Coming through a challenging market backdrop in 2019, our medium term priorities are clear. The execution of our innovation, growth and efficiency strategy will address our customers' most challenging problems whilst driving sustained value creation. We are excited about the potential at Elementis for material growth opportunities and margin improvement alongside strong cash generation."

 

Enhanced performance through applied innovation

Innovation is at the heart of what we do. Elementis is a global leader in performance-driven additives that help create innovative solutions for our customers. Leveraging our capabilities in rheology, surface chemistry and formulation, we help customers respond to their biggest challenges through deep partnerships, ongoing technical support and consistent quality, service and delivery. This focus on market leading innovation will drive our growth ambitions.

 

Growth - Personal Care, Talc and Coatings

Approximately 80% of Elementis' earnings are generated from Personal Care, Talc and Coatings; businesses with enduring competitive advantages and clear growth opportunities:

·; In Personal Care, the growth of premium cosmetics in Asia and natural skin care ingredients are clear opportunities for our unique hectorite clay and talc based ingredients. Emerging market growth and increasing product performance requirements will drive growth in the antiperspirant actives category. Elementis is well positioned to capture these attractive opportunities and grow revenue well above GDP levels with high and stable operating profit margins over the medium term.

 

·; As part of Elementis, Talc has been successfully integrated and is the global #2, serving growing high end industrial applications. It is well positioned to expand its market share outside of Europe and address the opportunities presented by global mega trends. Vehicle light weighting, emission regulations and reduced single use plastic consumption are expected

 

to drive strong sustainable demand for Elementis Talc ingredients. There is also significant revenue synergy potential (on track for $20- 25m by 2023) leveraging Elementis' global reach, customer relationships and innovation expertise. As a result, over the medium term Talc is expected to grow revenue well above GDP with an improving operating profit margin.

 

·; In Coatings we are a leading supplier of high value, premium additives, critical to performance. Our Coatings transformation programme has created an integrated, simpler and more customer centric organisation bringing margin improvement and focused, profitable growth. We see clear growth opportunities in premium decorative, waterborne industrial additives, adhesives & sealants and talc. We are targeting GDP+ organic revenue growth over the medium term, with an improving operating profit margin.

 

Efficiency and simplification - $15m of fixed cost savings by 2022

We remain intent on building a more efficient business and fit for purpose organisation to strengthen our platform for growth and increase our agility. In addition to the $10m cost savings being delivered in 2019, we aim to deliver a further $15m of savings by 2022. This is comprised of approximately $5m organisational efficiencies and around $10m global supply chain savings from network efficiency and optimising third party production. A key enabler of these savings will be the further digitisation of Elementis, as we create a simpler and faster operating model and IT infrastructure.

 

Strong operating cash flow to continue - disciplined capital allocation

Elementis is targeting operating cash conversion of at least 90% per annum with underlying growth in adjusted operating profit and is on track for $30m of working capital savings by 2020 with more to come thereafter. Capex is expected to be approximately $50m per annum of which over half will be growth and productivity oriented, including a $20m investment in a new site in Mumbai, India starting up in H2 2020.

 

Financial deleveraging focus - under 1.5x EBITDA

Financial deleveraging is a key focus. The execution of our medium term innovation, growth and efficiency priorities combined with strong cash generation will drive a clear deleveraging profile. Our medium term leverage objective is under 1.5x EBITDA, with further reduction thereafter.

 

Enquiries

Elementis plc

James Curran, Investor Relations

 

Tel: 020 7067 2994

Tulchan

Martin Robinson/David Allchurch

 

 

Tel: 020 7353 4200

Elementis Plc will be hosting a presentation for analysts and investors covering the Group's refreshed strategy and targets starting at 2.30pm today. The presentation will be webcast live at www.elementis.com . A recording of the webcast will be made available on the website shortly after the presentation.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
 
END
 
 
MSCGGGWCGUPBGRR
Date   Source Headline
12th Apr 202411:33 amRNSDirector/PDMR Shareholding
12th Apr 202411:28 amRNSDirector/PDMR Shareholding
9th Apr 20246:04 pmRNSDirector/PDMR Shareholding
26th Mar 20244:07 pmRNSAnnual Financial Report & Notice of AGM
19th Mar 20243:02 pmRNSAdditional Listing
15th Mar 20241:00 pmRNSDirectorate Change
12th Mar 20244:38 pmRNSDirector/PDMR Shareholding
12th Mar 20244:33 pmRNSDirector/PDMR Shareholding
8th Mar 20245:56 pmRNSDirector/PDMR Shareholding
7th Mar 20247:00 amRNSDirectorate changes
7th Mar 20247:00 amRNSPreliminary results year ended 31 December 2023
1st Mar 20249:30 amRNSBlock listing Interim Review
18th Jan 20247:00 amRNSTrading Update
2nd Jan 20249:45 amRNSTotal Voting Rights
1st Dec 202310:46 amRNSTotal Voting Rights
30th Nov 20239:38 amRNSDirector/PDMR Shareholding
14th Nov 20237:00 amRNS2023 Capital Markets Day
1st Nov 20239:46 amRNSTotal Voting Rights
31st Oct 20237:00 amRNSThird Quarter Trading Update
2nd Oct 20239:34 amRNSTotal Voting Rights
20th Sep 202312:09 pmRNSResponse to open letter from Franklin Templeton
12th Sep 20233:13 pmRNSDirector Declaration
8th Sep 20239:30 amRNSHolding(s) in Company
1st Sep 20239:49 amRNSBlock listing Interim Review
1st Sep 20239:42 amRNSTotal Voting Rights
1st Aug 20239:44 amRNSTotal Voting Rights
27th Jul 20232:16 pmRNSHolding(s) in Company
27th Jul 20237:00 amRNSHalf-year Report
20th Jul 202312:58 pmRNSHolding(s) in Company
3rd Jul 202310:21 amRNSTotal Voting Rights
29th Jun 20234:29 pmRNSDirector/PDMR Shareholding
23rd Jun 20239:32 amRNSDirector/PDMR Shareholding
30th May 20238:06 amRNSDirector Declaration
2nd May 20239:37 amRNSTotal Voting Rights
26th Apr 20232:12 pmRNSResult of AGM
26th Apr 20237:00 amRNSAGM Trading Statement
17th Apr 202310:15 amRNSDirector/PDMR Shareholding
17th Apr 202310:10 amRNSDirector/PDMR Shareholding
13th Apr 20234:24 pmRNSDirector/PDMR Shareholding
3rd Apr 202311:28 amRNSDirector Declaration
3rd Apr 20239:34 amRNSTotal Voting Rights
24th Mar 20239:27 amRNSDirector/PDMR Shareholding
22nd Mar 20234:02 pmRNSAnnual Financial Report & Notice of AGM
17th Mar 20232:58 pmRNSAdditional Listing
14th Mar 20237:30 amRNSDirector Declaration
9th Mar 20232:50 pmRNSDirector/PDMR Shareholding
9th Mar 20232:47 pmRNSDirector/PDMR Shareholding
7th Mar 20237:00 amRNSPreliminary results year ended 31 December 2022
1st Mar 20239:53 amRNSBlock listing Interim Review
1st Mar 20239:39 amRNSTotal Voting Rights

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.